Reengineering Hope: CAR-T Therapy for Multipl...
Up next
Recommended Episodes
CAR T cells are genetically engineered to express a receptor that recognizes and kills tumor cells. CAR T-cell products are now FDA approved for 6 hematologic malignancies. Author Jennifer N. Brudno, MD, National Cancer Institute, joins JAMA Deputy Editor Mary McGrae McDermott ...
<span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Drs. John Sweetenham and Shaji Kumar discuss the emergence of CAR T-cell therapy for multiple myeloma, its benefits and challenges for patients, and its potential role earlier in the treatment of diseas ...